After-Hours Movers Oct 30, 2026: Why INO, CLRO, CAPR Jumped

INO — Inovio Pharmaceuticals, Inc. (+241.7%)

Inovio jumped after the bell, trading up 241.7% to $2.05 versus its 4:00 PM ET regular-session close. About 79.7 million shares changed hands after hours, against a 20-day average of roughly 5.9 million for a full day. Market cap is only $62.0M, so this is a micro-cap.

Why is INO up? The FDA granted accelerated approval to Voceryq (INO-3107), Inovio's treatment for recurrent respiratory papillomatosis, a rare disease. Stocktwits described it as the company's first approved product. Reuters reported the approval came on a Friday, and Investing.com said it arrived on the PDUFA target date, the deadline the FDA sets for its decision. Different outlets quoted different after-hours gains, from about 215% to roughly 280%, because quotes shift quickly on thin trading. Stocktwits also reported that rival PGEN fell 27% after hours on the news.

The technical picture was weak going in. RSI was 27, the moving-average stack was bearish, and the stock sat 77.9% below its 52-week high. Its relative strength rating was 7, conviction was 36/100 (grade D), and the trend-template score was 0. No chart pattern signal was active.

The short setup adds fuel. The squeeze score is 78/100. Short interest is 19.25 million shares, or 4.4 days to cover. That is how long it would take shorts to buy back their positions at average volume. A short-sale restriction was active. Free float is 99.2%, so this is not a low-float story. The smart-money score is 20/100, with a largest disclosed stake of 10.3%.

After-hours moves happen on thin liquidity and can extend or reverse at the next open. A gap this large often retraces in part.

CLRO — ClearOne Inc (+32.8%)

ClearOne traded up 32.8% to $4.55 after hours on 3.6 million shares, about half its 20-day average of 7.6 million. Market cap is just $9.2M.

No news, filing or announcement explains the gain. The only company-specific item for October 30 was a delay. Vivani Medical said its deal to fold its Cortigent unit into ClearOne remains pending final regulatory approval. The parties now expect to close shortly after approval rather than in October 2026. That reads as a negative, not a catalyst for a rally. Earlier spikes followed the July merger agreement and the August shareholder consent. Treat this after-hours move as momentum- or technically-driven, and verify the price against a live feed.

The technicals are soft. RSI is 47, ADX is 24, and the moving-average stack is bearish. The stock is 79.2% below its 52-week high. Conviction is 36/100 (grade D) and the trend-template score is 1. An 8-K on October 13 flagged a delisting matter, which is bearish. Another on October 15 covered an agreement.

The squeeze score is only 21/100. Short interest is 24,903 shares, or 0.5 days to cover, and free float is 32.7%. A holder owns 61.3%, which limits tradable supply. A short-sale restriction was active. Stocks like this swing hard in both directions. See our Oct 26 recap for earlier action.

CAPR — Capricor Therapeutics, Inc. (+11.9%)

Capricor rose 11.9% to $7.15 after hours on 3.35 million shares, above its 20-day average of 2.7 million. Market cap is $371.5M.

No news, filing or announcement explains the move. The only recent filing was a Schedule 13G/A stake change on October 14, which was neutral. The move looks momentum- or technically-driven.

The stock is 84.2% below its 52-week high. RSI is 42, ADX is 14 (a weak trend), and the moving-average stack is bearish. The relative strength rating is 99, but conviction is 36/100 (grade D) and the trend-template score is 2.

The squeeze score is 67/100. Short interest is 22.18 million shares, or 2.0 days to cover, with a 71.7% free float and 65% short-volume. A short squeeze is when shorts rush to buy back shares and push the price higher. The smart-money score is 29/100, with a largest disclosed stake of 7.1%.

PCLA — PicoCELA Inc. (+8.2%)

PicoCELA rose 8.2% to $8.93 after hours on about 1.01 million shares, below its 20-day average of 1.52 million. Market cap is $79.3M. We covered the stock in the Oct 29 top movers recap.

No news, filing or announcement explains the move. Recent headlines from trading-focused sites describe volatile price action. The only recent filing was a neutral 6-K on October 5. This looks momentum-driven.

The technicals are the strongest of the four. The moving-average stack is bullish, RSI is 57, ADX is 40 (a strong trend), and the trend-template score is 6. Relative strength is 99 and technical rank is 98. Conviction is just 4/100 (grade D), and no pattern signal was active. The stock is 57.9% below its 52-week high. A related read is our ADX guide.

Free float is only 3.5%, so very few shares trade. That can exaggerate moves. The squeeze score is 48/100. Short interest is 124,766 shares, or 0.2 days to cover. A short-sale restriction was active.

The bottom line

Inovio's after-hours surge has a clear, researched cause: an FDA approval. The other three movers have no clear catalyst. After-hours trading is thin, so prices can gap and reverse at the next open. Chasing extended gainers is high-risk. Patterns and squeezes fail often, and big one-day moves often give back gains. Manage risk, size positions small and do your own research. This is educational content, not financial advice.

StockSetups scans the full US universe after every close and every premarket morning. It surfaces patterns, squeeze scores and conviction in one place. See also our Oct 29 after-hours recap.